Drugs / Expanded unmodified autologous CD4+ T cells
Expanded unmodified autologous CD4+ T cells
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03666871 Comparator | Jun 2019 → Jan 2024 | HIV infectious disease | University of Cincinnati | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Expanded unmodified autologous CD4+ T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03666871 ↗ |
| Modality | Cell therapy | “Autologous CD4+ T cells without ex vivo modification of the CCR5 gene by zinc finger nucleases” NCT03666871 ↗ |
| Route | Intravenous | “single intravenous infusion” NCT03666871 ↗ |